

Staff (see **ADDRESSES**). A link to the transcript will also be available on the internet at <https://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/NationalAntimicrobialResistanceMonitoringSystem/ucm059172.htm>.

Dated: September 15, 2017.

Anna K. Abram,

Deputy Commissioner for Policy, Planning, Legislation, and Analysis.

[FR Doc. 2017-20108 Filed 9-20-17; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of Single-Award Deviation From Competition Requirements for the Severe Combined Immunodeficiency (SCID) Newborn Screening Program at the Jeffrey Modell Foundation

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of award.

SUMMARY: HRSA announces the award of an extension in the amount of \$2,000,000 for the Severe Combined Immunodeficiency (SCID) Newborn Screening program at the Jeffrey Modell Foundation (JMF). The extension will allow JMF, the cooperative agreement recipient, during the budget period of May 1, 2017 to April 30, 2018, to provide technical assistance and support to states for the implementation of population based newborn screening for SCID.

FOR FURTHER INFORMATION CONTACT: Jill F. Shuger, ScM, Division of Services for Children with Special Health Needs, MCHB, HRSA, 5600 Fishers Lane, Rockville, Maryland 20857, Phone: (301) 443-3247, Email: JShuger@hrsa.gov.

SUPPLEMENTARY INFORMATION:

Intended Recipient of the Award: Jeffrey Modell Foundation.

Amount of Non-Competitive Awards: \$2,000,000.

Budget Period of Supplemental Funding: May 1, 2017 to April 30, 2018. *CFDA Number:* 93.110.

Authority: Public Health Service Act, § 1109, as amended by the Newborn Screening Saves Lives Reauthorization Act of 2014 (Public Law 110-204) (42 U.S.C. 300b-8).

Justification: The Maternal and Child Health Bureau (MCHB) is proposing that JMF continue activities under the current cooperative agreement to ensure the implementation of newborn screening for SCID in all 50 states, particularly in the states that have yet to implement SCID screening (*i.e.*, Alabama, Arizona, Indiana, Kansas, Louisiana, Nevada and North Carolina). Using its resources and centers, JMF will provide technical assistance in areas of funding, state government education, and linkage to expert care and patient access to a national network of specialized treatment centers. Further, JMF will continue to support states with implementation of SCID screening and follow up as well as the immediate treatment of infants identified with SCID. JMF will use the data collected from the states to educate clinical immunologists, neonatologists and other providers on effective screening for SCID. Additionally, JMF will continue to support education and awareness of newborn screening for SCID to families and health care providers and provide education to primary care providers and medically underserved populations.

Grantee/organization name	Grant No.	State	Fiscal year 2017 authorized funding level	Fiscal year 2017 estimated supplemental funding
Jeffrey Modell Foundation	UG5MC28325	UT	\$2,000,000	\$2,000,000

Dated: September 7, 2017.

George Sigounas,

Administrator.

[FR Doc. 2017-20116 Filed 9-20-17; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial

property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; T32 Institutional Training Grant Review.

Date: October 6, 2017.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Dental and Craniofacial Research, Democracy One, 6701 Democracy Blvd., Suite 602, Bethesda, MD 20892.

Contact Person: Kan Ma, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH, 6701 Democracy Boulevard, Suite 814, Bethesda, MD 20892, 301-451-4838, mak2@mail.nih.gov.

Name of Committee: National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Division of

Musculoskeletal Diseases RISK R61/R33 Peer Review.

Date: October 11, 2017.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Rd, Bethesda, MD 20852.

Contact Person: Xincheng Zheng, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH, 6701 Democracy Boulevard, Suite 820, Bethesda, MD 20892, 301-451-4838, xincheng.zheng@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: September 15, 2017.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-20095 Filed 9-20-17; 8:45 am]

BILLING CODE 4140-01-P